Amendments to the Claims

Please amend Claims 15-29, 82, 114, 121, 129, and 150. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1-14 (Cancelled)

15. (Currently Amended) A pharmaceutical composition, comprising a compound represented by [[of]] Formula III,



(III)

or a physiologically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient, wherein:

R_8 is an unsubstituted alkyl; an alkyl group substituted with one or more groups selected from fluoro, chloro, bromo, iodo, nitro, hydroxyl, $-NR_{13}R_{14}$, $-C(O)R_{15}$, cyano and cycloalkyl; a substituted or unsubstituted aryl; an aralkyl substituted in the aromatic portion of the aralkyl; a heteroaralkyl substituted in the heteroaryl portion of the heteroaralkyl; an aralkyl or heteroaralkyl substituted in the alkyl portion of the aralkyl or heteroaralkyl with one or more groups selected from fluoro, chloro, bromo, iodo, nitro, hydroxyl, $-NR_{13}R_{14}$, $-C(O)R_{15}$, cyano and cycloalkyl; or an unsubstituted aralkyl or heteroaralkyl;

R_9 is a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heteroaralkyl;

R_{10} is alkyl substituted with $NR_{13}R_{14}$, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaralkyl, or a substituted or unsubstituted heterocycloalkylalkyl;

R_{11} is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaralkyl, a substituted or unsubstituted benzophenone, or a substituted or unsubstituted cycloalkylalkyl;

R_{12} is H;

$NR_{13}R_{14}$ is a heterocycloalkyl, and

R_{15} is -H, an alkyl, an aryl or an aralkyl.

16. (Currently Amended) The composition~~compound~~ of Claim 15, wherein R_8 is substituted or unsubstituted phenyl, phenyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl, linear C_1-C_{12}-alkyl, branched C_1-C_{12}-alkyl, cyclic C_3-C_{12}-alkyl, or dicycloalkyl-C_1-C_4-alkyl.

17. (Currently Amended) The composition~~compound~~ of Claim 16, wherein R_8 is phenyl, phenyl-C_1-C_4-alkyl, or diphenyl-C_1-C_4-alkyl wherein the phenyl group or phenyl groups optionally bear one or more substituents independently selected from the group consisting of C_1-C_4-alkoxy, C_1-C_4-alkyl and cyano.

18. (Currently Amended) The composition~~compound~~ of Claim 17, wherein the phenyl group or phenyl groups bear one or more substituents independently selected from the group consisting of methoxy, methyl, ethyl and cyano.

19. (Currently Amended) The composition~~compound~~ of Claim 15, wherein R_8 is selected from the group consisting of 2,2-diphenylethyl, 2-(4-ethylphenyl)ethyl, benzyl, diphenylmethyl, 1,2-diphenylethyl, 3,3-diphenylpropyl, 3,4,5-trimethoxybenzyl, 2,4,4-

trimethylisopentyl, 2-(4-methoxyphenyl)ethyl, 2-cyclopentyl-2-phenylethyl, or 2-phenyl-2-pyridylethyl.

20. (Currently Amended) The compositioncompound of Claim 15, wherein R_9 is substituted or unsubstituted phenyl, substituted or unsubstituted phenyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl, phenylfuranyl or heteroaryl-C_1-C_4-alkyl.

21. (Currently Amended) The compositioncompound of Claim 20, wherein R_9 is phenyl, phenyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl wherein the phenyl group or phenyl groups bear one or more substituents independently selected from the group consisting of cyano, C_1-C_4-alkyl-S-, a halogen, a halogenated C_1-C_4-alkyl, C_1-C_4-alkoxy, trifluoromethyl, and substituted and unsubstituted phenoxy.

22. (Currently Amended) The compositioncompound of Claim 20, wherein R_9 is phenyl, phenyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl wherein the phenyl group or phenyl groups bear one or more substituents independently selected from the group consisting of cyano, methyl, methoxy, phenoxy, chloro-substituted phenoxy, methoxy-substituted phenoxy and methyl-substituted phenoxy.

23. (Currently Amended) The compositioncompound of Claim 15, wherein R_9 is phenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, diphenylmethyl, pyrazolylmethyl, 2,4-dimethylphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-methyl-4-methoxyphenyl, 3-methyl-4-methoxyphenyl, 4-methylthiophenyl, 3-chlorophenyl, 3-trifluoromethylphenyl, benzyl, 2-trifluoromethylbenzyl, 3-trifluoromethylbenzyl, 2-chlorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 2-methoxybenzyl, 3-methoxybenzyl, 4-methoxybenzyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 3-azidylphenyl, 3-(4-methoxyphenoxy)phenyl, or 5-phenylfuran-2-yl.

24. (Currently Amended) The compositioncompound of Claim 15, wherein R_{10} is substituted or unsubstituted phenyl, unsubstituted heteroaraalkyl group, unsubstituted heterocycloalkylalkyl group, or an alkyl substituted with $-NR_{13}R_{14}$.

25. (Currently Amended) The compositioncompound of Claim 24, wherein R_{10} is 2-(imidazol-4-yl)ethyl, 3-(imidazol-4-yl)propyl, 3-(imidazol-1-yl)propyl 2-(3-methylimidazol-4-yl)ethyl, 2-(morpholin-4-yl)ethyl, 2-(4-pyrazolyl)ethyl, 4-pyrazolylmethyl, 2-N,N-dimethylaminoethyl, 3-N,N-dimethylaminopropyl, or 2-(aminocarbonyl)phenyl.

26. (Currently Amended) The compositioncompound of Claim 15, wherein R_{11} is a linear or branched C_1-C_4-alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted benzophenonyl, pyrazolyl, aminopyrazolyl, substituted or unsubstituted indolyl-C_1-C_4-alkyl, thiophenyl, quinoxaline, substituted or unsubstituted phenyl-C_1-C_4-alkyl, pyridylcarbonylphenyl, phenylcarbonyl-C_1-C_4-alkyl, naphthyl, naphthyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl, C_5-C_8-cycloalkyl-C_1-C_4-alkyl, C_1-C_4-alkylcarbonyl-C_1-C_4-alkyl, fluorenyl, pyrrolylpryrrolyl, N-methylpyrrolyl, or pyridyl.

27. (Currently Amended) The compositioncompound of Claim 26, wherein R_{11} is a phenyl, phenyl-C_1-C_4-alkyl, phenylcarbonyl-C_1-C_4-alkyl, naphthyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl, C_5-C_8-cycloalkyl-C_1-C_4-alkyl, fluorenyl or pyridyl substituted with one or more substituents independently selected from C_1-C_4-alkyl and C_1-C_4-alkoxy.

28. (Currently Amended) The compositioncompound of Claim 26, wherein R_{11} is a benzophenonyl group, wherein said benzophenonyl group is substituted with a C_1-C_4-alkoxy group, a C_1-C_4-alkyl group or a chlorine atom.

29. (Currently Amended) The compositioncompound of Claim 15, wherein R_{11} is benzophenon-2-yl, 4'-methoxybenzophenon-2-yl, 4'-chlorobenzophenon-2-yl, 2-(furan-2-yl)phenyl, 2-(thiophen-2-yl)phenyl, 2-benzylphenyl, 2-pyridylcarbonylphenyl, 2-

(phenoxymethyl)phenyl, 2-(*t*-butylcarbonyl)phenyl, 2,2-diphenylethyl, 1-fluorenyl, (naphth-2-yl)methyl, naphth-1-yl, 3-(phenylcarbonyl)propyl, 4-phenylbutyl, 4-butylphenyl, 2-(4-chlorophenylcarbonyl)phenyl, 3-methoxyphenyl, N-methylpyrrol-2-yl, 2,3-dimethoxyphenyl, 3-butyl-2-pyridyl, 2-naphthylmethyl, 2-cyclohexylethyl, 3-methoxyphenyl, N-methyl-2-pyrrolyl, 2-cyclopentylethyl, 3-oxobutyl, 2-benzopyrazyl, quinoxalin-2-yl, 3-idolyl, (2-methylindol-3-yl)methyl, 3-(indol-3-yl)propyl, (indol-3-yl)methyl, (5-bromoindol-3-yl)methyl, 3-chlorophenyl, 3-aminopyrazol-4-yl, 2-(indol-3-yl)-1-hydroxyethyl, 3-fluorophenyl, 1-phenyl-1-hydroxymethyl, 2-phenylphenyl, 2-phenoxyphenyl, thiophen-2-yl, or isopropyl.

30. (Previously Presented) A composition comprising an enantiomeric mixture of a compound represented by the following structural formula:



or a physiologically acceptable salt thereof.

31. (Previously Presented) A compound which has a positive specific rotation, wherein the compound is represented by the following structural formula:



or a physiologically acceptable salt thereof.

32. (Previously Presented) A compound which has a negative specific rotation, wherein the compound is represented by the following structural formula:



or a physiologically acceptable salt thereof.

33-70 (Cancelled)

71. (Previously Presented) A method of treating a TNF-α mediated condition in a patient, wherein the TNF-mediated disease is rheumatoid arthritis, sepsis, inflammatory bowel disease, allergic encephalitis or multiple sclerosis, comprising administering to the patient a therapeutically effective amount of a compound of Formula III,



(III)

or a physiologically acceptable salt thereof, wherein:

R_8 is an unsubstituted alkyl; an alkyl group substituted with one or more groups selected from fluoro, chloro, bromo, iodo, nitro, hydroxyl, $-NR_{13}R_{14}$, $-C(O)R_{15}$, cyano and cycloalkyl; a substituted or unsubstituted aryl; an aralkyl substituted in the aromatic portion of the aralkyl; a heteroaralkyl substituted in the heteroaryl portion of the heteroaralkyl; an aralkyl or heteroaralkyl substituted in the alkyl portion of the aralkyl or heteroaralkyl with one or more groups selected from fluoro, chloro, bromo, iodo, nitro, hydroxyl, $-NR_{13}R_{14}$, $-C(O)R_{15}$, cyano and cycloalkyl; or an unsubstituted aralkyl or heteroaralkyl;

R_9 is a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heteroaralkyl;

R_{10} is alkyl substituted with $NR_{13}R_{14}$, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaralkyl, or a substituted or unsubstituted heterocycloalkylalkyl;

R_{11} is a substituted or unsubstituted alkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted heteroaralkyl, a substituted or unsubstituted benzophenonyl, or a substituted or unsubstituted cycloalkylalkyl;

R_{12} is -H;

$NR_{13}R_{14}$ is a heterocycloalkyl, and

R_{15} is -H, an alkyl, an aryl or an aralkyl.

72. (Previously Presented) The method of Claim 71, wherein R_8 is substituted or unsubstituted phenyl, phenyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl, linear C_1-C_{12}-alkyl, branched C_1-C_{12}-alkyl, cyclic C_3-C_{12}-alkyl, or dicycloalkyl-C_1-C_4-alkyl.

73. (Previously Presented) The method of Claim 72, wherein R_8 is phenyl, phenyl-C_1-C_4-alkyl, or diphenyl-C_1-C_4-alkyl wherein the phenyl group or phenyl groups bear one or more substituents independently selected from the group consisting of C_1-C_4-alkoxy, C_1-C_4-alkyl and cyano.

74. (Previously Presented) The method of Claim 73, wherein the phenyl group or phenyl groups bear one or more substituents independently selected from the group consisting of methoxy, methyl and cyano.

75. (Previously Presented) The method of Claim 71, wherein R_8 is selected from the group consisting of 2,2-diphenylethyl, 2-(4-ethylphenyl)ethyl, benzyl, diphenylmethyl, 1,2-diphenylethyl, 3,3-diphenylpropyl, 3,4,5-trimethoxybenzyl, 2,4,4-trimethylisopentyl, 2-(4-methoxyphenyl)ethyl, 2-cyclopentyl-2-phenylethyl, or 2-phenyl-2-pyridylethyl.

76. (Previously Presented) The method of Claim 71 wherein R_9 is substituted or unsubstituted phenyl, phenyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl, phenylfuranyl or heteroaryl-C_1-C_4-alkyl.

77. (Previously Presented) The method of Claim 76, wherein R_9 is phenyl, phenyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl wherein the phenyl group or phenyl groups bear one or more substituents independently selected from the group consisting of cyano, C_1-C_4-alkyl-S-, a halogen C_1-C_4-alkyl, C_1-C_4-alkoxy, trifluoromethyl, and substituted and unsubstituted phenoxy.

78. (Previously Presented) The method of Claim 76, wherein R_9 is phenyl, phenyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl wherein the phenyl group or phenyl groups bear one or more

substituents independently selected from the group consisting of cyano, methyl, methoxy, phenoxy, chloro-substituted phenoxy, methoxy-substituted phenoxy and methyl-substituted phenoxy.

79. (Previously Presented) The method of Claim 71, wherein R_9 is phenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, diphenylmethyl, pyrazolylmethyl, 2,4-dimethylphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-methyl-4-methoxyphenyl, 3-methyl-4-methoxyphenyl, 4-methylthiophenyl, 3-chlorophenyl, 3-trifluoromethylphenyl, benzyl, 2-trifluoromethylbenzyl, 3-trifluoromethylbenzyl, 2-chlorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 2-methoxybenzyl, 3-methoxybenzyl, 4-methoxybenzyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 3-azidylphenyl, 3-(4-methoxyphenoxy)phenyl, or 5-phenylfuran-2-yl.

80. (Previously Presented) The method of Claim 71, wherein R_{10} is substituted or unsubstituted phenyl, unsubstituted heteroaraalkyl group, unsubstituted heterocycloalkylalkyl group, or an alkyl substituted with $-NR_{13}R_{14}$.

81. (Original) The method of Claim 80, wherein R_{10} is 2-(imidazol-4-yl)ethyl, 3-(imidazol-4-yl)propyl, 3-(imidazol-1-yl)propyl 2-(3-methylimidazol-4-yl)ethyl, 2-(morpholin-4-yl)ethyl, 2-(4-pyrazolyl)ethyl, 4-pyrazolylmethyl, 2-N,N-dimethylaminoethyl, 3-N,N-dimethylaminopropyl, and 2-(aminocarbonyl)phenyl.

82. (Currently Amended) The method of Claim 71, wherein R_{11} is a linear or branched C_1-C_4-alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted benzophenonyl, pyrazolyl, aminopyrazolyl, substituted or unsubstituted indolyl-C_1-C_4-alkyl, thiophenyl, quinoxaline, substituted or unsubstituted phenyl-C_1-C_4-alkyl, pyridylcarbonylphenyl, phenylcarbonyl-C_1-C_4-alkyl, naphthyl, naphthyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl, C_5-C_8-cycloalkyl-C_1-C_4-alkyl, C_1-C_4-alkylcarbonyl-C_1-C_4-alkyl, fluorenyl, pyrrolylpyrrolyl, N-methylpyrrolyl, or pyridyl.

83. (Original) The method of Claim 82, wherein R_{11} is a phenyl, phenyl-C_1-C_4-alkyl, phenylcarbonyl-C_1-C_4-alkyl, naphthyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl, C_5-C_8-cycloalkyl-C_1-C_4-alkyl, fluorenyl or pyridyl substituted with one or more substituents independently selected from C_1-C_4-alkyl and C_1-C_4-alkoxy.

84. (Original) The method of Claim 82, wherein R_{11} is a benzophenonyl group, wherein said benzophenonyl group is substituted with a C_1-C_4-alkoxy group, a C_1-C_4-alkyl group or a chlorine atom.

85. (Original) The method of Claim 71, wherein R_{11} is benzophenon-2-yl, 4'-methoxybenzophenon-2-yl, 4'-chlorobenzophenon-2-yl, 2-(furan-2-yl)phenyl, 2-(thiophen-2-yl)phenyl, 2-benzylphenyl, 2-pyridylcarbonylphenyl, 2-(phenoxymethyl)phenyl, 2-(*t*-butylcarbonyl)phenyl, 2,2-diphenylethyl, 1-fluorenyl, (naphth-2-yl)methyl, naphth-1-yl, 3-(phenylcarbonyl)propyl, 4-phenylbutyl, 4-butylphenyl, 2-(4-chlorophenylcarbonyl)phenyl, 3-methoxyphenyl, N-methylpyrrol-2-yl, 2,3-dimethoxyphenyl, 3-butyl-2-pyridyl, 2-naphthylmethyl, 2-cyclohexylethyl, 3-methoxyphenyl, N-methyl-2-pyrrolyl, 2-cyclopentylethyl, 3-oxobutyl, 2-benzopyrazyl, quinoxalin-2-yl, 3-idolyl, (2-methylindol-3-yl)methyl, 3-(indol-3-yl)propyl, (indol-3-yl)methyl, (5-bromoindol-3-yl)methyl, 3-chlorophenyl, 3-aminopyrazol-4-yl, 2-(indol-3-yl)-1-hydroxyethyl, 3-fluorophenyl, 1-phenyl-1-hydroxymethyl, 2-phenylphenyl, 2-phenoxyphenyl, thiophen-2-yl, or isopropyl.

86-97 (Cancelled)

98. (Previously Presented) A method of treating a TNF-α mediated condition in a patient, wherein the TNF-mediated disease is rheumatoid arthritis, sepsis, inflammatory bowel disease, allergic encephalitis or multiple sclerosis, comprising the step of administering to the patient a therapeutically effective amount of a compound represented by the following structural formula:



or a physiologically acceptable salt thereof.

99. (Original) The method of Claim 98, wherein the compound has a positive specific rotation.

100. (Original) The method of Claim 98, wherein the compound has a negative specific rotation.

101-108 (Cancelled)

109. (Previously Presented) A compound according to Formula III:



(III)

or a physiologically acceptable salt thereof, wherein;

R_8 is an unsubstituted alkyl; an alkyl group substituted with one or more groups selected from fluoro, chloro, bromo, iodo, nitro, hydroxyl, $-NR_{13}R_{14}$, $-C(O)R_{15}$, cyano and cycloalkyl; a substituted or unsubstituted aryl; an aralkyl substituted in the aromatic portion of the aralkyl; a heteroaralkyl substituted in the heteroaryl portion of the heteroaralkyl; or an unsubstituted aralkyl or heteroaralkyl;

R_9 is a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heteroaralkyl;

R_{10} is an alkyl substituted with $NR_{13}R_{14}$ or a substituted or unsubstituted heteroaralkyl;

R_{11} is a substituted or unsubstituted alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted cycloalkylalkyl, or a substituted or unsubstituted benzophenone

R_{12} is H;

$NR_{13}R_{14}$ is a heterocycloalkyl, and

R_{15} is -H, an alkyl, an aryl or an aralkyl.

110. (Previously Presented) A compound according to Claim 109 wherein R_{10} is an unsubstituted heteroaralkyl.

111. (Previously Presented) A compound according to Claim 110 wherein said heteroaraalkyl is C_{1-6} alkyl pyridyl, C_{1-6} alkyl pyrimidyl, C_{1-6} alkyl quinolyl, C_{1-6} alkyl isoquinolyl, C_{1-6} alkyl pyrrolyl, C_{1-6} alkyl quinoxalyl, C_{1-6} alkyl imidazolyl, C_{1-6} alkyl oxazolyl, C_{1-6} alkyl

isoxazolyl, C_{1-6} alkyl pyrazolyl, C_{1-6} alkyl thienyl, C_{1-6} alkyl furanyl, C_{1-6} alkyl pyrazolyl, C_{1-6} alkyl thiadiazolyl, C_{1-6} alkyl oxadiazolyl, C_{1-6} alkyl indazolyl, C_{1-6} alkyl thiazolyl, C_{1-6} alkyl isothiazolyl, C_{1-6} alkyl tetrazolyl, C_{1-6} alkyl benzo (b) thienyl, C_{1-6} alkyl benzimidazolyl, C_{1-6} alkyl benzoxazolyl, C_{1-6} alkyl benzothiazolyl, C_{1-6} alkyl benzothiadiazolyl, C_{1-6} alkyl benzoxadiazolyl, C_{1-6} alkyl indolyl, C_{1-6} alkyl tetrahydroindolyl, C_{1-6} alkyl azaindolyl, C_{1-6} alkyl indazolyl, C_{1-6} alkyl quinolinyl, C_{1-6} alkyl imidazopyridyl, C_{1-6} alkyl puryl, C_{1-6} alkyl pyrrolo[2,3-d]pyrimidyl, C_{1-6} alkyl pyrazolo[3,4-d]pyrimidyl.

112. (Previously Presented) A compound according to Claim 111 wherein R_9 is unsubstituted or substituted aryl.

113. (Previously Presented) A compound according to Claim 112 wherein R_9 is substituted or unsubstituted phenyl.

114. (Currently Amended) A compound according to Claim 110 wherein R_{11} is an unsubstituted or substituted benzophenonyl, pyrazolyl, aminopyrazolyl, substituted or unsubstituted indolyl-C_1-C_4-alkyl, thiophenyl, quinoxaline, substituted or unsubstituted phenyl-C_1-C_4-alkyl, pyridylcarbonylphenyl, phenylcarbonyl-C_1-C_4-alkyl, naphthyl, naphthyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl, C_5-C_8-cycloalkyl-C_1-C_4-alkyl, C_1-C_4-alkylcarbonyl-C_1-C_4-alkyl, fluorenyl, pyrrolylpyrrolyl, N-methylpyrrolyl, or pyridyl.

115. (Previously Presented) A compound according to Claim 114 wherein R_{11} is unsubstituted or substituted benzophenonyl.

116. (Previously Presented) A compound according to Claim 109 wherein R_8 is phenyl, phenyl-C_1-C_4-alkyl, or diphenyl-C_1-C_4-alkyl wherein the phenyl group or phenyl groups optionally bear one or more substituents independently selected from the group consisting of C_1-C_4-alkoxy, C_1-C_4-alkyl and cyano.

117. (Previously Presented) The compound of Claim 116, wherein R_8 is selected from the group consisting of 2,2-diphenylethyl, 2-(4-ethylphenyl)ethyl, benzyl, diphenylmethyl, 1,2-diphenylethyl, 3,3-diphenylpropyl, 3,4,5-trimethoxybenzyl, 2,4,4-trimethylisopentyl, 2-(4-methoxyphenyl)ethyl, 2-cyclopentyl-2-phenylethyl, or 2-phenyl-2-pyridylethyl.

118. (Previously Presented) A compound according to formula:



(III)

or a physiologically acceptable salt thereof, wherein;

R_8 is an unsubstituted alkyl; an alkyl group substituted with one or more groups selected from fluoro, chloro, bromo, iodo, nitro, hydroxyl, $-NR_{13}R_{14}$, $-C(O)R_{15}$, cyano and cycloalkyl; a substituted or unsubstituted aryl; an aralkyl substituted in the aromatic portion of the aralkyl; a heteroaralkyl substituted in the heteroaryl portion of the heteroaralkyl; or an unsubstituted aralkyl or heteroaralkyl;

R_9 is a substituted or unsubstituted phenyl;

R_{10} is a C_1-C_6 alkyl imidazolyl;

R_{11} is a substituted or unsubstituted alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted benzophenone or a substituted or unsubstituted cycloalkylalkyl; and

R_{12} is H,

$NR_{13}R_{14}$ is a heterocycloalkyl, and

R_{15} is -H, an alkyl, an aryl or an aralkyl.

119. (Previously Presented) A compound according to Claim 118 wherein R_8 is phenyl, phenyl-C_1-C_4-alkyl, or diphenyl-C_1-C_4-alkyl wherein the phenyl group or phenyl groups

bear one or more substituents independently selected from the group consisting of C_1-C_4-alkoxy, C_1-C_4-alkyl and cyano.

120. (Previously Presented) The compound of Claim 119, wherein R_8 is selected from the group consisting of 2,2-diphenylethyl, 2-(4-ethylphenyl)ethyl, benzyl, diphenylmethyl, 1,2-diphenylethyl, 3,3-diphenylpropyl, 3,4,5-trimethoxybenzyl, 2,4,4-trimethylisopentyl, 2-(4-methoxyphenyl)ethyl, 2-cyclopentyl-2-phenylethyl, or 2-phenyl-2-pyridylethyl.

121. (Currently Amended) A compound according to Claim 118 wherein R_{11} is an unsubstituted or substituted benzophenonyl, pyrazolyl, aminopyrazolyl, substituted or unsubstituted indolyl-C_1-C_4-alkyl, thiophenyl, quinoxaline, substituted or unsubstituted phenyl-C_1-C_4-alkyl, pyridylcarbonylphenyl, phenylcarbonyl-C_1-C_4-alkyl, naphthyl, naphthyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl, C_5-C_8-cycloalkyl-C_1-C_4-alkyl, C_1-C_4-alkylcarbonyl-C_1-C_4-alkyl, fluorenyl, pyrrolyl~~pryrrolyl~~, N-methylpyrrolyl, or pyridyl.

122. (Previously Presented) A compound according to Claim 121 wherein R_{11} is substituted or unsubstituted benzophenonyl.

123. (Previously Presented) A method of treating a TNF-α mediated condition in a patient, wherein the TNF-mediated disease is rheumatoid arthritis, sepsis, inflammatory bowel disease, allergic encephalitis or multiple sclerosis, comprising administering to a patient a therapeutically effective amount of:



(III)

or a physiologically acceptable salt thereof, wherein

R_8 is an unsubstituted alkyl; an alkyl group substituted with one or more groups selected from fluoro, chloro, bromo, iodo, nitro, hydroxyl, $-NR_{13}R_{14}$, $-C(O)R_{15}$, cyano and cycloalkyl; a substituted or unsubstituted aryl; an aralkyl substituted in the aromatic portion of the aralkyl; a heteroaralkyl substituted in the heteroaryl portion of the heteroaralkyl; or an unsubstituted aralkyl or heteroaralkyl;

R_9 is a substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted heteroaryl or a substituted or unsubstituted heteroaralkyl;

R_{10} is an alkyl substituted with $NR_{13}R_{14}$, or a substituted or unsubstituted heteroaralkyl;

R_{11} is a substituted or unsubstituted alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted cycloalkylalkyl, or a substituted or unsubstituted benzophenone;

R_{12} is -H; and

$NR_{13}R_{14}$ is a heterocycloalkyl, and

R_{15} is -H, an alkyl, an aryl or an aralkyl.

124. (Previously Presented) The method according to Claim 123 wherein R_{10} is an unsubstituted heteroaralkyl.

125. (Cancelled)

126. (Previously Presented) The method according to Claim 124 wherein said heteroaraalkyl is C_{1-6} alkyl pyridyl, C_{1-6} alkyl pyrimidyl, C_{1-6} alkyl quinolyl, C_{1-6} alkyl isoquinolyl, C_{1-6} alkyl pyrrolyl, C_{1-6} alkyl quinoxalyl, C_{1-6} alkyl imidazolyl, C_{1-6} alkyl oxazolyl, C_{1-6} alkyl isoxazolyl, C_{1-6} alkyl pyrazolyl, C_{1-6} alkyl thienyl, C_{1-6} alkyl furanyl, C_{1-6} alkyl pyrazolyl, C_{1-6} alkyl thiadiazolyl, C_{1-6} alkyl oxadiazolyl, C_{1-6} alkyl indazolyl, C_{1-6} alkyl thiazolyl, C_{1-6} alkyl isothiazolyl, C_{1-6} alkyl tetrazolyl, C_{1-6} alkyl benzo (b) thienyl, C_{1-6} alkyl benzimidazolyl, C_{1-6} alkyl benzoxazolyl, C_{1-6} alkyl benzothiazolyl, C_{1-6} alkyl benzothiadiazolyl, C_{1-6} alkyl benzoxadiazolyl, C_{1-6} alkyl indolyl, C_{1-6} alkyl tetrahydroindolyl, C_{1-6} alkyl azaindolyl, C_{1-6} alkyl indazolyl, C_{1-6} alkyl quinolinyl, C_{1-6}

alkyl imidazopyridyl, C_{1-6} alkyl puryl, C_{1-6} alkyl pyrrolo[2,3-d]pyrimidyl, or C_{1-6} alkyl pyrazolo[3,4-d]pyrimidyl.

127. (Previously Presented) The method according to Claim 126 wherein R_9 is unsubstituted or substituted aryl.

128. (Previously Presented) The method according to Claim 127 wherein R_9 is substituted or unsubstituted phenyl.

129. (Currently Amended) The method according to Claim 123 wherein R_{11} is an unsubstituted or substituted benzophenonyl, pyrazolyl, aminopyrazolyl, substituted or unsubstituted indolyl-C_1-C_4-alkyl, thiophenyl, quinoxaline, substituted or unsubstituted phenyl-C_1-C_4-alkyl, pyridylcarbonylphenyl, phenylcarbonyl-C_1-C_4-alkyl, naphthyl, naphthyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl, C_5-C_8-cycloalkyl-C_1-C_4-alkyl, C_1-C_4-alkylcarbonyl-C_1-C_4-alkyl, fluorenyl, pyrrolylpyrrolyl, N-methylpyrrolyl, or pyridyl.

130. (Previously Presented) The method according to Claim 129 wherein R_{11} is unsubstituted or substituted benzophenonyl.

131. (Previously Presented) The method according to Claim 123 wherein R_8 is phenyl, phenyl-C_1-C_4-alkyl, or diphenyl-C_1-C_4-alkyl wherein the phenyl group or phenyl groups optionally bear one or more substituents independently selected from the group consisting of C_1-C_4-alkoxy, C_1-C_4-alkyl and cyano.

132. (Previously Presented) The method of Claim 131, wherein the phenyl group or phenyl groups optionally bear one or more substituents independently selected from the group consisting of methoxy, methyl, ethyl and cyano.

133. (Previously Presented) The method of Claim 131, wherein R_8 is selected from the group consisting of 2,2-diphenylethyl, 2-(4-ethylphenyl)ethyl, benzyl, diphenylmethyl, 1,2-

diphenylethyl, 3,3-diphenylpropyl, 3,4,5-trimethoxybenzyl, 2,4,4-trimethylisopentyl, 2-(4-methoxyphenyl)ethyl, 2-cyclopentyl-2-phenylethyl, or 2-phenyl-2-pyridylethyl.

134-146 (Cancelled)

147. (Previously Presented) A method of treating a TNF-α mediated condition in a patient, wherein the TNF-mediated disease is rheumatoid arthritis, sepsis, inflammatory bowel disease, allergic encephalitis or multiple sclerosis, comprising administering to a patient a therapeutically effective amount of formula:



(III)

or a physiologically acceptable salt thereof, wherein;

R_8 is an unsubstituted alkyl; an alkyl group substituted with one or more groups selected from fluoro, chloro, bromo, iodo, nitro, hydroxyl, $-NR_{13}R_{14}$, $-C(O)R_{15}$, cyano and cycloalkyl; a substituted or unsubstituted aryl; an aralkyl substituted in the aromatic portion of the aralkyl; a heteroaralkyl substituted in the heteroaryl portion of the heteroaralkyl; or an unsubstituted aralkyl or heteroaralkyl;

R_9 is a substituted or unsubstituted phenyl;

R_{10} is a C_1-C_6 alkyl imidazolyl;

R_{11} is a substituted or unsubstituted alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted benzophenone or a substituted or unsubstituted cycloalkyalkyl;

R_{12} is hydrogen; and

$NR_{13}R_{14}$ is a heterocycloalkyl, and

R_{15} -H, an alkyl, an aryl or an aralkyl.

148. (Previously Presented) The method according to Claim 147 wherein R_8 is is phenyl, phenyl-C_1-C_4-alkyl, or diphenyl-C_1-C_4-alkyl wherein the phenyl group or phenyl groups bear one or more substituents independently selected from the group consisting of C_1-C_4-alkoxy, C_1-C_4-alkyl and cyano.

149. (Previously Presented) The method according Claim 148, wherein R_8 is selected from the group consisting of 2,2-diphenylethyl, 2-(4-ethylphenyl)ethyl, benzyl, diphenylmethyl, 1,2-diphenylethyl, 3,3-diphenylpropyl, 3,4,5-trimethoxybenzyl, 2,4,4-trimethylisopentyl, 2-(4-methoxyphenyl)ethyl, 2-cyclopentyl-2-phenylethyl, or 2-phenyl-2-pyridylethyl.

150. (Currently Amended) The method according to Claim 147 wherein R_{11} is an unsubstituted or substituted benzophenonyl, pyrazolyl, aminopyrazolyl, substituted or unsubstituted indolyl-C_1-C_4-alkyl, thiophenyl, quinoxaline, substituted or unsubstituted phenyl-C_1-C_4-alkyl, pyridylcarbonylphenyl, phenylcarbonyl-C_1-C_4-alkyl, naphthyl, naphthyl-C_1-C_4-alkyl, diphenyl-C_1-C_4-alkyl, C_5-C_8-cycloalkyl-C_1-C_4-alkyl, C_1-C_4-alkylcarbonyl-C_1-C_4-alkyl, fluorenyl, pyrrolylpryrrolyl, N-methylpyrrolyl, or pyridyl.

151. (Previously Presented) The method according to Claim 150 wherein R_{11} is substituted or unsubstituted benzophenonyl.

152-160 (Cancelled)